Interleukin 28B (IL28B) Polymorphism (rs12979860), Saliva
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Predicting responsiveness of genotype 1 hepatitis C viral infections to combined pegylated-interferon and ribavirin-based therapies
This saliva-based test is especially useful for establishing the IL28B genotype in patients who received a heterologous blood transfusion, in the preceding 45 days (6 weeks) or allogeneic bone marrow transplants.
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Polymerase Chain Reaction (PCR) Followed by 5'-Nuclease End-Point Allelic Discrimination Analysis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
IL28B Polymorphism Genotype, Saliva